X4 Pharmaceuticals (XFOR)
Commercializing XOLREMDI while advancing mavorixafor for chronic neutropenia.
$4.01
Pre-market−0.04 (−0.87%)
At close$4.05(−0.61%)
Something off on this page? Send us feedback.
Next report
Nov 4, 2026
in 62 days
EPS estimate
−$0.20
Revenue estimate
$2.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$0.04−$3.47−$0.69−$0.22−$0.16−$0.13−$0.13Pending
Estimate−$4.13−$4.53−$0.79−$0.36−$0.20−$0.18−$0.18−$0.20
Surprise+101.0%+23.4%+12.7%+38.9%+20.0%+26.1%+26.1%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$28.8M$2.0M$1.8M$2.6M$2.7M$8.8M$8.8MPending
Estimate$1.9M$2.2M$1.7M$1.7M$3.2M$2.4M$2.4M$2.3M
Surprise+1,416.2%−11.4%+1.8%+48.2%−15.4%+263.9%+263.9%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.18 | −$0.13 | +26.1% |
| Aug 2026 | −$0.18 | −$0.13 | +26.1% |
| May 2026 | −$0.20 | −$0.16 | +20.0% |
| Mar 2026 | −$0.36 | −$0.22 | +38.9% |
The latest year is open to everyone — the 37 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Sep 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Mar 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.20 | — | — | $2.3M | — | — | — |
| Aug 7, 2026 | −$0.18 | −$0.13 | +26.1% | $2.4M | $8.8M | +263.9% | −8.4% |
| Aug 6, 2026 | −$0.18 | −$0.13 | +26.1% | $2.4M | $8.8M | +263.9% | +11.3% |
| May 6, 2026 | −$0.20 | −$0.16 | +20.0% | $3.2M | $2.7M | −15.4% | −2.1% |
| Mar 17, 2026 | −$0.36 | −$0.22 | +38.9% | $1.7M | $2.6M | +48.2% | −4.3% |
The latest year is open to everyone — the 37 quarters behind it read with an account. Sign in | |||||||
| Nov 5, 2025 | |||||||
| Aug 8, 2025 | |||||||
| May 1, 2025 | |||||||
| Mar 25, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 21, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 17, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Jul 30, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 15, 2019 | |||||||
| Mar 11, 2019 | |||||||
| Nov 9, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 9, 2018 | |||||||
| Nov 17, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Mar 30, 2016 | |||||||